Authors' recommendations: Recommendations to the Minister of Public Health and the competent bodies at NIHDI (RIZIV – INAMI) - KCE recommends to take into account the different clinical and health-economic findings, as summarized in Table 1, in the decision-making process on the (further) reimbursement of bevacizumab. - For stage IV patients, the results of the ongoing studies should be followed up. - Currently, no economic evaluations are requested for the reimbursement request for an extension of indications of class 1 drugs. Because the cost-effectiveness of the same drug in a different indication may be very different, we recommend to also request an economic evaluation for the extension to other indications. Recommendations to the manufacturers of drugs and medical devices - In the design of future clinical studies, from the beginning, we recommend to incorporate overall survival and quality of life as endpoints, in addition to progression-free survival. - According to the EUnetHTA guidelines on measuring health-related quality of life, disease-specific and generic utility instruments (such as EQ-5D) should both be included in the research protocols. We recommend to follow these guidelines and to report the results in a transparent way.

Project Status: Completed

Year Published: 2017

URL for published report: https://doi.org/10.57598/R285C

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Belgium

DOI: 10.57598/R285C

Organisation Name: Belgian Health Care Knowledge Centre

Contact Address: Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85

Contact Name: info@kce.fgov.be

Contact Email: info@kce.fgov.be

Copyright: Belgian Health Care Knowledge Centre (KCE)